How do you pay?

How to pay the least

Ask for the cash price

Rubraca

We didn’t find one.

  1. Ask your pharmacy for Rubraca’s cash price, and one or two other pharmacies too.
  2. Rubraca’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameRubraca
Authorized genericrucaparib
Regular genericrucaparib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Rubraca?
The original
–
–

Brand nameThe maker’s card

RUBRACA Co-Pay Assistance Program

Savings card from pharmaand GmbH

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a prescription

Sign up on rubraca.com 

Or call 1-844-779-7707.

In the maker’s words

“Pay as little as $0 if you’re an eligible patient with private or commercial insurance who has been prescribed RUBRACA.”

From the maker’s offer on rubraca.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Rubraca itself, from the same company, sold without the brand name, and usually for less. For now Rubraca is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:

Ovarian cancer

  • for the maintenance treatment of adult patients with a deleterious BRCAmutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

Prostate cancer

  • for the treatment of adult patients with a deleterious BRCAmutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA.

Source: the FDA label for Rubraca (pharmaand GmbH), December 31, 2025. Full label on DailyMed 

Good to know